Phastar tells Pharmafocus how data can be used to improve research innovations in rare diseases
Jonathan Bowen considers the use of indication-based agreements to remove barriers to patient access to combination cancer therapies
Veeva explains the best ways that biopharma companies can boost their engagement
Betsy Goodfellow considers why community pharmacies are closing and how this will impact the general public
Page 4 – Contaminated cough syrup leads to WHO Medical Product Alert
Page 6 – First official long COVID-19 treatment could emerge from the NIH’s RECOVER initiative
Page 8 – Jemperli by GSK approved to treat endometrial cancer
Page 10 – American Heart Association grants $2.1m for research into possible link between CVD, migraines and strokes
Page 12 – Rare disease treatments to be researched in partnership between Pfizer and AstraZeneca’s Alexion
Executive Director
– PMGroup Worldwide Ltd
Karl Equi
Group Managing Editor
Iona Everson
Editorial Assistants
Betsy Goodfellow
betsy@pharmafile.com
Sales Manager
Eliot Haynes
Design & Layout
Peter May
Pharmafocus is published by:
Samedan Ltd
Suite E, 11 Bell Yard Mews,
175 Bermondsey Street,
London, SE1 3TN
Tel: +44 (0)20 7724 3456
Fax: +44 (0)20 7403 7747
Subscriptions & Data Management
Curwood CMS Tel: 01580 883840
ISSN: 1465-5403
Pharmafocus is sent free of charge to selected permanent employees of ethical and OTC pharmaceutical and biotech companies. Employees are specifiers from middle and senior management with responsibility for making buying decisions. Selection is at the discretion of the Publisher. Copies are also available on a subscription basis at an annual fee of £115 (UK), £145 (Europe) and £185 (RoW).
All subscriptions payable to Samedan. Back copies can be purchased for £15.00 each. Pharmafocus is published by Samedan Ltd. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form without permission, unless for the purposes of reference and comment.
©2022 Samedan Ltd, Pharmaceutical Publishers
The opinions and views expressed by contributors to this publication are not necessarily those of the Editor or the Publisher and, while every care has been taken in the preparation of the newspaper, the Editor and the Publisher are not responsible for such opinions and views, or for any inaccuracies in the articles. The Publisher is not responsible for any images supplied by contributors. While every care is taken with artwork supplied, the Publisher cannot be held responsible for any loss or damage incurred. The entire content of this publication is protected by copyright. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form, by any means – electronic, mechanical, photocopying or otherwise – without the prior permission of the Publisher.